Cardiac effects of dapagliflozin in diabetic rats with subacute exposure

Boran T., Ulus Karaca B., Karagöz Köroğlu A., Kaptan E., Ercan F., Özhan G.

ISTANBUL JOURNAL OF PHARMACY, vol.52, no.1, pp.8-13, 2022 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 52 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.26650/istanbuljpharm.2022.1038546
  • Journal Indexes: Emerging Sources Citation Index (ESCI)
  • Page Numbers: pp.8-13
  • Keywords: Dapagliflozin, SGLT2 inhibitor, Type 2 diabetes mellitus, Cardio-protection, GLUCOSE COTRANSPORTER 2, OXIDATIVE STRESS, SGLT2 INHIBITOR, TROPONIN-T, CARDIOMYOPATHY, DIET
  • Istanbul University Affiliated: Yes


Background and Aims: Dapagliflozin (DAPA) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used for the treatment of type 2 diabetes mellitus (T2DM) as a monotherapy or combination therapy with other antidiabetic medicines. The Food and Drug Administration (FDA) recently approved DAPA to minimize the risk of hospitalization due to heart failure in patients with T2DM because of its antihypertensive and antihyperglycemic activities. However, further study of DAPA is necessary to ensure the safety of patients.